Aggressive Lymphomas
News
MRD data added to venetoclax label
The U.S.
From the Journals
TP53 mutation plus complex karyotype equals poor prognosis
The two markers signaled worse overall survival among mantle cell lymphoma patients.
Latest News
Novartis nabs first CAR T approval in Canada
Health Canada has approved its first chimeric antigen receptor (CAR) T-cell therapy, tisagenlecleucel (Kymriah).
News
First CAR T-cell therapy approved in Canada
Health Canada has authorized use of tisagenlecleucel (Kymriah™), making it the first chimeric antigen receptor (CAR) T-cell therapy to receive...
News
Regimens produce similar results in FL
Rituximab plus lenalidomide had efficacy similar to that of rituximab plus chemotherapy in the treatment of follicular lymphoma (FL) in a phase 3...
News
Ibrutinib maintains efficacy over time
Extended follow-up of the RESONATE-2 trial showed that first-line ibrutinib sustained efficacy in elderly patients with chronic lymphocytic...
From the Journals
RESONATE-2 update: First-line ibrutinib has sustained efficacy in older CLL patients
Adverse events were largely seen during the first year of treatment and decreased over time.
Feature
England green-lights coverage of one CAR T-cell therapy
Tisagenlecleucel (Kymriah) will be available for certain leukemia patients through the Cancer Drugs Fund.
From the Journals
Researchers find drug target in anaplastic large-cell lymphoma
A new study suggests TYK2 is expressed in all cases of ALCL.
From the Journals
Adverse events outweigh promise of SGN-CD70A against NHL
Despite a handful of durable remissions of non-Hodgkin lymphomas with the antibody-drug conjugate, thrombocytopenias canceled out the benefit.
News
Predicting early outcomes in DLBCL
Measurement of circulating tumor DNA (ctDNA) could be a new and useful tool for predicting survival outcomes and response to therapy in patients...